Skip to main content

Advertisement

SpringerLink
Log in

Annual rate of newly treated atrial fibrillation by age and gender in France, 2010–2016

  • CARDIOVASCULAR DISEASE
  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

Few studies are available on atrial fibrillation (AF) burden at a whole country scale. The objective was to estimate the rate of AF patients newly treated with oral anticoagulants (OAC) in France each year between 2010 and 2016 and to describe age and gender differences. We used the French national health data system. For each year between 2010 and 2016, we identified patients aged over 20 initiating OAC. OAC indicated for the treatment of AF was determined by hospitalization diagnoses, specific procedures and registered long-term disease status, or a multiple imputation process for patients with no recorded information as to why they initiated OAC. Among the 421,453 individuals initiating OAC treatment in 2016, the estimated number of newly treated AF patients was 210,131, women accounting for 46%, patients under 65 years old 17%, and 21.4% of patients living in most deprived area. Age-standardized rates reached 400/100,000 inhabitants. Approximately 19% of patients were recently hospitalized for heart failure and 7% for stroke. Age-standardized rates increased by 35% over the study period in both genders, with a marked increase in patients under 55 (+ 41%) and those over 85 years old (+ 60%). Annual rates of AF patients newly treated with OAC increased by 35% between 2010 and 2016. Important differences in rates were observed according to age, gender and the deprivation level of the living area.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ruddox V, Sandven I, Munkhaugen J, et al. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(14):1555–66.

    Article  Google Scholar 

  2. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47.

    Article  Google Scholar 

  3. Bejot Y, Ben Salem D, Osseby GV, et al. Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006. Neurology. 2009;72(4):346–53.

    Article  CAS  Google Scholar 

  4. Steffel J, Roldan-Schilling V, Rowell N, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93.

    Article  CAS  Google Scholar 

  5. Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;20(5):747–57.

    Article  Google Scholar 

  6. Yiin GS, Howard DP, Paul NL, et al. Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study. J Neurol Neurosurg Psychiatry. 2017;88(1):12–8.

    Article  Google Scholar 

  7. Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the systeme national d’information interregimes de l’Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149–67.

    Article  Google Scholar 

  8. Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–62.

    Article  Google Scholar 

  9. Billionnet C, Alla F, Berigaud E, et al. Identifying atrial fibrillation in outpatients initiating oral anticoagulants based on medico-administrative data: results from the French national healthcare databases. Pharmacoepidemiol Drug Saf. 2017;26(5):535–43.

    Article  CAS  Google Scholar 

  10. van Buuren S. Flexible imputation of missing data. 2nd ed. London: Chapman and Hall; 2018.

    Book  Google Scholar 

  11. Rey G, Jougla E, Fouillet A, et al. Ecological association between a deprivation index and mortality in France over the period 1997–2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:33.

    Article  Google Scholar 

  12. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.

    Article  Google Scholar 

  13. Huiart L, Ferdynus C, Renoux C, et al. Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. BMJ Open. 2018;8(3):e018180.

    Article  Google Scholar 

  14. Charlemagne A, Blacher J, Cohen A, et al. Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch Cardiovasc Dis. 2011;104(2):115–24.

    Article  Google Scholar 

  15. Cotte FE, Chaize G, Gaudin AF, et al. Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace. 2016;18(4):501–7.

    Article  Google Scholar 

  16. Fauchier L, Samson A, Chaize G, et al. Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study. Open Heart. 2015;2(1):e000290.

    Article  Google Scholar 

  17. Johansson C, Dahlqvist E, Andersson J, et al. Incidence, type of atrial fibrillation and risk factors for stroke: a population-based cohort study. Clin Epidemiol. 2017;9:53–62.

    Article  Google Scholar 

  18. Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15(4):486–93.

    Article  Google Scholar 

  19. Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993–2007. Circul Cardiovasc Qual Outcomes. 2012;5(1):85–93.

    Article  Google Scholar 

  20. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949–53.

    Article  Google Scholar 

  21. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25.

    Article  Google Scholar 

  22. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet (Lond Engl). 2015;386(9989):154–62.

    Article  Google Scholar 

  23. Stefansdottir H, Aspelund T, Gudnason V, et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace. 2011;13(8):1110–7.

    Article  Google Scholar 

  24. Barra S, Fynn S. Untreated atrial fibrillation in the United Kingdom: understanding the barriers and treatment options. J Saudi Heart Assoc. 2015;27(1):31–43.

    Article  Google Scholar 

  25. Gadsboll K, Staerk L, Fosbol EL, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38(12):899–906.

    PubMed  Google Scholar 

  26. Lacoin L, Lumley M, Ridha E, et al. Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD. BMJ Open. 2017;7(9):e015363.

    Article  Google Scholar 

  27. Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307–14.

    Article  Google Scholar 

  28. Steinberg BA, Gao H, Shrader P, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132–40.

    Article  CAS  Google Scholar 

  29. Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017;136(17):1588–97.

    PubMed  PubMed Central  Google Scholar 

  30. Sabouret P, Depret-Bixio L, Cotte FE, et al. Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database. Clin Res Cardiol. 2014;103(11):887–93.

    Article  Google Scholar 

  31. Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol. 2016;67(25):2913–23.

    Article  CAS  Google Scholar 

  32. Thompson LE, Maddox TM, Lei L, et al. Sex Differences in the use of oral anticoagulants for atrial fibrillation: a report from the national cardiovascular data registry (NCDR(®)) PINNACLE registry. J Am Heart Assoc. 2017;6(7):e005801.

    Article  Google Scholar 

  33. Savelieva I, Camm AJ. Female gender as a risk factor for stroke associated with atrial fibrillation. Eur Heart J. 2017;38(19):1480–4.

    Article  Google Scholar 

  34. Sjölander M, Eriksson M, Asplund K, et al. Socioeconomic inequalities in the prescription of oral anticoagulants in stroke patients with atrial fibrillation. Stroke. 2015;46(8):2220–5.

    Article  Google Scholar 

  35. Raparelli V, Proietti M, Butta C, et al. Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med. 2014;9(8):861–70.

    Article  Google Scholar 

  36. Jain V, Marshall IJ, Crichton SL, et al. Trends in the prevalence and management of pre-stroke atrial fibrillation, the South London Stroke Register, 1995–2014. PLoS ONE. 2017;12(4):e0175980–e80.

    Article  Google Scholar 

  37. Zoller B, Li X, Sundquist J, et al. Neighbourhood deprivation and hospitalization for atrial fibrillation in Sweden. Europace. 2013;15(8):1119–27.

    Article  Google Scholar 

Download references

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Non-Communicable Diseases, Santé Publique France, Saint Maurice, France

    Amélie Gabet, Edouard Chatignoux & Valérie Olié

  2. Department of Studies in Public Health, French National Health Insurance, Paris, France

    Cécile Billionnet & Géric Maura

  3. Team Pharmacoepidemiology, Inserm, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France

    Géric Maura

  4. Dijon Stroke Registry, EA 7460, University Hospital of Burgundy, Dijon, France

    Maurice Giroud & Yannick Béjot

Authors
  1. Amélie Gabet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edouard Chatignoux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cécile Billionnet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Géric Maura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maurice Giroud
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yannick Béjot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Valérie Olié
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AG directed research, wrote the manuscript; AG and EC performed the statistical analyses; EC, GM, CB and MG contributed to the discussion and reviewed the manuscript; YB and VO directed research, contributed to discussion and reviewed the manuscript. AG takes full responsibility for the data, the analyses and interpretation, and the conduct of the research.

Corresponding author

Correspondence to Amélie Gabet.

Ethics declarations

Coflict of interest

Dr. Béjot reports grants and personal fees from AstraZeneca, personal fees from Pfizer, personal fees from MSD, personal fees from Medtronic, personal fees from BMS, personal fees from Amgen, grants and personal fees from Boehringer-Ingelheim, outside the submitted work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 60 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gabet, A., Chatignoux, E., Billionnet, C. et al. Annual rate of newly treated atrial fibrillation by age and gender in France, 2010–2016. Eur J Epidemiol 35, 1139–1147 (2020). https://doi.org/10.1007/s10654-019-00594-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10654-019-00594-3

Keywords

Search

Navigation